For every disease state, understanding what happens to patients over time is critical to communicating the value of a product for treating a disease (or it complications). For example, event rates are used in building models, treatment effects can be estimated in populations that were not included in clinical trials, and long-term costs of care can be estimated and compared against models for validation purposes. In particular, these kinds of analyses are critical for conducting comparative effectiveness research.
We specialize in analyzing SEER-Medicare data, not only for solid tumors but also for lymphoma and leukemia (and eventually, myeloma). We have published our SEER Medicare work in a variety of journals, including Blood, BMC Cancer, Annals of Oncology, American Journal of Hematology, and Pharmacoeconomics.